Iambic closed a $100 million financing round to advance its Enchant and NeuralPLexer AI platforms, which the company says predict clinical endpoints and protein‑ligand structures to accelerate drug discovery. The funding follows publication of translational and early clinical data from Iambic’s lead programs. Separately, Terray Therapeutics unveiled EMMI, an AI selection model designed to prioritize molecules for real‑world synthesis, addressing the bottleneck between generative design and experimental testing. Both moves illustrate sustained VC and corporate interest in coupling generative models with selection systems to reduce synthesis burden and development risk. Investors and pharma partners will watch how these platforms translate predictions into reproducible preclinical candidates and how bespoke model training agreements and data partnerships affect time‑to‑candidate.